A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia
| Autor: | Francis Mégraud, J. F. Fléjou, Philippe Barthélémy, J. Laurent, A. Caekaert |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
medicine.medical_specialty
Hepatology medicine.diagnostic_test biology business.industry Urea breath test Gastroenterology macromolecular substances Helicobacter pylori Amoxicillin biology.organism_classification Surgery Metronidazole Internal medicine Clarithromycin Bacampicillin medicine Pharmacology (medical) business Omeprazole Antibacterial agent medicine.drug |
| Zdroj: | Alimentary Pharmacology & Therapeutics. 15:1787-1793 |
| ISSN: | 0269-2813 |
| DOI: | 10.1046/j.1365-2036.2001.01104.x |
| Popis: | Background: Helicobacter pylori eradication rates in France after therapy with omeprazole, amoxicillin and clarithromycin are among the lowest in Europe. This study evaluated alternative eradication regimens. Methods: Helicobacter pylori-positive patients (n=323) with non-ulcer dyspepsia were randomized to receive one of four 1-week regimens consisting of omeprazole, 20 mg b.d., plus either: amoxicillin, 1000 mg b.d., and clarithromycin, 500 mg b.d. (OAC); bacampicillin, 1200 mg b.d., and clarithromycin, 500 mg b.d. (OBC); clarithromycin, 250 mg b.d., and metronidazole, 500 mg b.d. (OCM); or amoxicillin, 1000 mg b.d, and azithromycin, 500 mg on day 1 and 250 mg on days 2–5 (OAAz). Eradication was confirmed by urea breath test 4–6 weeks after treatment. Susceptibility testing was performed in the case of eradication failure. Results: The eradication rate with OAAz was 38% (95% CI, 25.6–49.4) on intention-to-treat analysis, which was lower (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |